These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 33359641

  • 1. Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
    Vecchia DD, Kanazawa LKS, Wendler E, Hocayen PAS, Vital MABF, Takahashi RN, Da Cunha C, Miyoshi E, Andreatini R.
    Brain Res Bull; 2021 Mar; 168():63-73. PubMed ID: 33359641
    [Abstract] [Full Text] [Related]

  • 2. Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
    Vecchia DD, Kanazawa LKS, Wendler E, de Almeida Soares Hocayen P, Bruginski E, Campos FR, Stern CAJ, Vital MABF, Miyoshi E, Wöhr M, Schwarting RKW, Andreatini R.
    Behav Brain Res; 2018 Apr 16; 342():1-10. PubMed ID: 29307665
    [Abstract] [Full Text] [Related]

  • 3. Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
    Berghauzen-Maciejewska K, Kuter K, Kolasiewicz W, Głowacka U, Dziubina A, Ossowska K, Wardas J.
    Behav Brain Res; 2014 Sep 01; 271():343-53. PubMed ID: 24956561
    [Abstract] [Full Text] [Related]

  • 4. Investigation of non-invasive focused ultrasound efficacy on depressive-like behavior in hemiparkinsonian rats.
    Herlihy RA, Alicandri F, Berger H, Rehman H, Kao Y, Akhtar K, Dybas E, Mahoney-Rafferty E, Von Stein K, Kirby R, Tawfik A, Skumurski R, Feustel PJ, Molho ES, Shin DS.
    Exp Brain Res; 2024 Feb 01; 242(2):321-336. PubMed ID: 38059986
    [Abstract] [Full Text] [Related]

  • 5. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin.
    Santiago RM, Barbiero J, Gradowski RW, Bochen S, Lima MM, Da Cunha C, Andreatini R, Vital MA.
    Behav Brain Res; 2014 Feb 01; 259():70-7. PubMed ID: 24183944
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
    Ferro MM, Angelucci ME, Anselmo-Franci JA, Canteras NS, Da Cunha C.
    Braz J Med Biol Res; 2007 Jan 01; 40(1):89-96. PubMed ID: 17225001
    [Abstract] [Full Text] [Related]

  • 7. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.
    Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN.
    Neuroscience; 2008 Oct 28; 156(4):830-40. PubMed ID: 18817851
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neuronal degeneration and oxidative stress in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment.
    Haddadi R, Eyvari-Brooshghalan S, Nayebi AM, Sabahi M, Ahmadi SA.
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Dec 28; 393(12):2427-2437. PubMed ID: 32715318
    [Abstract] [Full Text] [Related]

  • 10. Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's Disease.
    Ilkiw JL, Kmita LC, Targa ADS, Noseda ACD, Rodrigues LS, Dorieux FWC, Fagotti J, Dos Santos P, Lima MMS.
    Mol Neurobiol; 2019 Feb 28; 56(2):1082-1095. PubMed ID: 29869198
    [Abstract] [Full Text] [Related]

  • 11. Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies.
    Brand SJ, Harvey BH.
    Acta Neuropsychiatr; 2017 Aug 28; 29(4):207-221. PubMed ID: 27692010
    [Abstract] [Full Text] [Related]

  • 12. Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors.
    Réus GZ, Abelaira HM, dos Santos MA, Carlessi AS, Tomaz DB, Neotti MV, Liranço JL, Gubert C, Barth M, Kapczinski F, Quevedo J.
    Behav Brain Res; 2013 Nov 01; 256():451-6. PubMed ID: 24004850
    [Abstract] [Full Text] [Related]

  • 13. The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
    Santiago RM, Tonin FS, Barbiero J, Zaminelli T, Boschen SL, Andreatini R, Da Cunha C, Lima MM, Vital MA.
    Neuroscience; 2015 Aug 06; 300():246-53. PubMed ID: 25999296
    [Abstract] [Full Text] [Related]

  • 14. Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model.
    Jiang Y, Wang Y, Sun X, Lian B, Sun H, Wang G, Du Z, Li Q, Sun L.
    Brain Behav; 2017 Aug 06; 7(8):e00749. PubMed ID: 28828210
    [Abstract] [Full Text] [Related]

  • 15. Guanosine prevents depressive-like behaviors in rats following bilateral dorsolateral striatum lesion induced by 6-hydroxydopamine.
    Marques NF, Binder LB, Roversi K, Sampaio TB, Constantino LC, Prediger RD, Tasca CI.
    Behav Brain Res; 2019 Oct 17; 372():112014. PubMed ID: 31212060
    [Abstract] [Full Text] [Related]

  • 16. Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test.
    Owolabi RA, Akanmu MA, Adeyemi OI.
    Neurosci Lett; 2014 Apr 30; 566():172-6. PubMed ID: 24530380
    [Abstract] [Full Text] [Related]

  • 17. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels.
    Garcia LS, Comim CM, Valvassori SS, Réus GZ, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J.
    Basic Clin Pharmacol Toxicol; 2008 Dec 30; 103(6):502-6. PubMed ID: 19067677
    [Abstract] [Full Text] [Related]

  • 18. Blockade of calcium-permeable AMPA receptors in the lateral habenula produces increased antidepressant-like effects in unilateral 6-hydroxydopamine-lesioned rats compared to sham-lesioned rats.
    Zhang J, Wang Y, Sun YN, Li LB, Zhang L, Guo Y, Wang T, Yao L, Chen L, Liu J.
    Neuropharmacology; 2019 Oct 30; 157():107687. PubMed ID: 31251995
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of Substantia Nigra pars compacta lesion on the behavioral sequencing in the 6-OHDA model of Parkinson's disease.
    Casarrubea M, Di Giovanni G, Crescimanno G, Rosa I, Aiello S, Di Censo D, Ranieri B, Santangelo A, Busatta D, Cassioli E, Galante A, Alecci M, Florio TM.
    Behav Brain Res; 2019 Apr 19; 362():28-35. PubMed ID: 30630014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.